Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Liver diseases and hyperlipidemia]

S Jiao1, H Hiraoka, Y Matsuzawa

  • 1Second Department of Internal Medicine, Osaka University Medical School.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|November 1, 1990
PubMed
Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predicting neuroendocrine neoplasm grade with dual tracer positron emission tomography/computed tomography (PET/CT) using <sup>18</sup>F-fluorodeoxyglucose (<sup>18</sup>F-FDG) and <sup>18</sup>F-AlF-NOTA-octreotide: a lesion-based analysis.

Clinical radiology·2024
Same author

Impact of the combined timing of PD-1/PD-L1 inhibitors and chemotherapy on the outcomes in patients with refractory lung cancer.

ESMO open·2021
Same author

Impacts of Glycemic Control on Intracranial Plaque in Patients with Type 2 Diabetes Mellitus: A Vessel Wall MRI Study.

AJNR. American journal of neuroradiology·2020
Same author

[Clinical features of cerebral amyloid angiopathy characterized by cortical superficial siderosis].

Zhonghua yi xue za zhi·2019
Same author

LncRNA PRNCR1 promoted the progression of eclampsia by regulating the MAPK signal pathway.

European review for medical and pharmacological sciences·2018
Same author

EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer.

Oncogene·2017
Same journal

[Development of novel therapeutics for multiple myeloma and improvement of drug lag].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Clinical pharmacy services to patients of immunomodulatory drugs].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Therapeutic drug monitoring of the new anti-myeloma drugs in the treatment of multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[The evaluation of minimal residual disease in multiple myeloma by an allele-specific oligonucleotide real-time PCR].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Evaluation of minimal residual disease in myeloma by multiparametric flow cytometry].

Nihon rinsho. Japanese journal of clinical medicine·2019
See all related articles